Kinase Inhibitors: Global Markets

July 03, 2012

Wellesley, Mass. – According to a new technical market research report, KINASE INHIBITORS: GLOBAL MARKETS (BIO053C) from BCC Research (www.bccresearch.com), global revenues for kinase inhibitors were nearly $29.1 billion in 2011 and are projected to reach nearly $40.3 billion in 2016, a five-year compound annual growth rate (CAGR) of 6.7%.

The kinase inhibitors market can be broken down into four regions: the United States, Europe, Asia, and emerging markets.

The United States accounted for $10.4 billion in 2011 and should reach $11.6 billion in 2016, a CAGR of 2.2%.

Europe totaled nearly $9.4 billion in 2011 and should reach $11.6 billion in 2016, a CAGR of 4.4%.

Asia, worth nearly $5.1 billion in 2011, is projected to reach nearly $8.6 billion in 2016, a CAGR of 11%.

Emerging markets accounted for nearly $4.2 billion in 2011 and in 2016 should account for nearly $8.5 , a CAGR of 15.2%.

The kinase inhibitors market is seeing an increasing number of novel kinase inhibitors being utilized in the current industry in human trials. The kinase inhibitors field is seeing an increase in the development of next-generation inhibitors that target cancers and other diseases, including inflammation. As the field matures, market leaders are attempting to answer questions in regards to technologies and methods used or in relation to novel targets and therapeutic approaches relating to kinase inhibitors.

Roche/Genentech and Novartis are current leaders in the kinase inhibitors market. More and more companies are investing in research to address issues such as resistance, selectivity versus safety, developing lead compounds, and integrating chemistry and biology into development, as well as utilizing the latest technologies and techniques such as fragment- and structure-based design to develop new products.

This study contributes to the areas of market growth in kinase inhibitor manufacture and use. Pharmaceutical biotechnical companies, research institutes, and physicians will find this study to be of interest.

In addition to BIO053C, BCC has also recently published BIO108A, BIO109A, BIO110A, and BIO111A. These reports cover kinase inhibitor markets with focuses, respectively, in the U.S., Europe, Asia, and emerging market regions.

To Contact us, click here  

Kinase Inhibitors: Global Markets( BIO053C )
Publish Date: Jun 2012    

Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email press@bccresearch.com or visit www.bccresearch.com/media to request access to our library of market research.